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Background: The resistance of cephalosporins is significantly serious in veterinary clinic. In order to inhibit the
bacterial resistance production, the mutant selection window (MSW) hypothesis with Escherichia coli (E. coli) ATCC
25922 exposed to cefquinome in an animal tissue-cage model was investigated.
Results: Localized infection with E. coli was established in piglets, and the infected animals were administrated
intramuscularly with various doses and intervals of cefquinome to provide antibiotic concentrations below the
MIC99, between the MIC99 and the mutant prevention concentration (MPC), and above the MPC. E. coli lost
susceptibility when drug concentrations fluctuated between the lower and upper boundaries of the window, which
defined in vitro as the MIC99 (0.06 μg/mL) and the MPC (0.16 μg/mL) respectively. For PK/PD parameters, there were
no mutant selection enrichment when T>MIC99 was ≤ 25% or T>MPC was ≥ 50% of administration interval. When
T>MIC99 was > 25% and T>MPC was <50% of administration interval, resistance selection was observed. When
AUC24 h/MIC99 and AUC24 h/MPC were considered, the mutant selection window extended from 32.84 h to
125.64 h and from 12.83 h to 49.09 h, respectively.
Conclusions: These findings demonstrate that the MSW exists in vivo for time-dependent antimicrobial agents, and
its boundaries fit well with those determined in vitro. Maintenance of antimicrobial concentrations above the MPC
for > 50% of administration interval is a straightforward way to restrict the acquisition of resistance in this tissue
cage model. This situation was achieved with daily intramuscular doses of 1 mg cefquinome/kg body weight.
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The development of bacterial resistance has resulted from
a variety of factors, including drug overuse and drug
misuse [1], both in the environment and during therapy
[2]. Even the commonly accepted treatment strategy of
killing susceptible pathogens contributes to the problem
by allowing selective amplification of resistant mutants
during the treatment [3]. According to a proposed hypothe-
sis, resistant mutants selectively amplify at antibiotic con-
centrations within the mutant selection window (MSW),
drug concentrations between the boundary of MIC99* Correspondence: hzding@scau.edu.cn
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concentration (MPC that inhibits growth of the least-
susceptible single-step mutant subpopulation) [4].
The mutant selection window hypothesis was initially
proposed using agar plate assays [5], and then explored in
several in vitro or in vivo model [6-11]. However, as far as
we know, the time-dependent drugs such as cephalosporin
were rarely reported. Cefquinome is a fourth generation
broad-spectrum cephalosporin antibiotic, which was deve-
loped solely for veterinary use and approved for the treat-
ment of respiratory tract disease, acute mastitis and footrot
in cattle, calf septicaemia, respiratory diseases in pigs and
metritis-mastitis-agalactia syndrome in sow [12,13]. In
order to reduce the occurring of cefquinome resistance
and even the resistance gene transmission between herdhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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which could be used as a framework for the design of
dosage regimen of cefquinome therapy.
Localized infection is particularly suitable for determin-
ation the mutant selection window hypothesis in in vivo
[4]. One feasible system is the tissue-cage infection model
[4,14], which used a tissue-cage with holes on its surface
implanted surgically into subcutaneous tissue of an ani-
mal. In piglets? body, the surface of the cage becomes
encapsulated by connective tissue 2-4 weeks after implant-
ation, and the interior is filled with tissue-cage fluid.
Bacterial cultures are injected into the cage and remained
there until eliminated by host defenses and antimicrobial
treatment.
In this study, above 1010 CFU of E. coli ATCC 25922
were injected into the tissue-cages implanted in piglets,
and various doses and intervals of cefquinome were
administered intramuscularly. The objective was to valid-
ate that the resistant mutants would be selected predom-
inantly when drug concentrations maintained inside a
concentration window, the boundaries of which deter-
mined by agar plate assays. It is hoped that this model
would have the capability to provide a clear demonstration
of the mutant selection window in vivo and support argu-
ments for how antimicrobial dosage regimens adjustment
could severely restrict the amplification and enrichment of
resistant mutant for cefquinome.
Methods
Antimicrobials and chemicals
Penicillin, as a sodium salt for injection, and cefquinome
for injection were purchased from Hebei Yuanzheng
Pharmaceutical Co., Ltd., P.R. China. Cefquinome stan-
dard was from China Institute of Veterinary Drugs Control,
Beijing, P.R. China. Acetonitrile and formic acid (chroma-
tography grade) were from Fisher Scientific.
MIC99, MIC, and MPC determination
E. coli strain ATCC 25922 stored at -70?C was grown in
Mueller-Hinton broth or on Mueller-Hinton agar.
MIC99 and MPC were determined as described elsewhere
[15]. Briefly, for MIC99, bacterial cultures were grown
overnight (≥10 h) in the constant temperature oscillation
incubator at 37?C, 220 r/min, normal atmosphere, serially
diluted, and approximately 106 cells were applied to agar
plates containing various concentrations of cefquinome.
After incubation at 37?C for 16-18 h, bacterial colonies
were counted, and the fraction relative to the bacterial
inoculum was calculated. Drug concentration that inhib-
ited growth by 99% was defined as MIC99. For MPC,
above 1010 cells were applied to multiple cefquinome-
containing agar plates. After incubation at 37?C for a total
of 96 h and the examination of the appearance of colonies
every 24 h, MPC was recorded as the lowest antibioticconcentration at which no colonies grew on an agar
plate. The MIC99 and MPC were determined in the five
independent experiments.
Tissue-cage infection model
Healthy castrated cross-bred piglets (Duroc ? Landrace ?
Yorkshire),weight ranging from 25 to 30 kg, were
housed individually and fed antibiotic-free food twice a
day. Water was available ad libitum. The experimental
protocol was approved by the Committee on the Ethics
of animals of South China Agricultural University
(Approval number 2013-01; 15 March 2013).
The tissue-cages were made in-house from platinum-
cured medical grade silicone tubing (Medical silicon, SF
Medical; Beijing Jingcheng Chuangye Medical Instru-
ment Co., Ltd., Beijing, P.R. China) and modified slightly
from similar cages described by Sidhu et al. [16]. Briefly,
the dimensions of the tissue-cages were of 65 mm
length, 18 mm external diameter and 13 mm internal
diameter. Each cage had 24 identical holes and each hole
has a surface area of 9.6 mm2; the total exchange surface
area was 2.3 cm2.
Two tissue-cages were implanted subcutaneously in
each animal, one on either side of the neck approxi-
mately equidistant from the jugular vein and spinal cord
under aseptic conditions. Surgical insertion was carried
out under deep sedation (pentobarbital sodium) and
local infiltration anaesthesia (procainamide hydrochlor-
ide injection) in piglets. After surgery, the piglets were
treated with intramuscular penicillin (160 000 IU/kg)
twice a day for 3-5 days to prevent infection. The non-
steroidal anti-inflammatory drug (NSAID) was provided
for analgesia in post-operation simultaneously. By 4 weeks
after implantation, each tissue-cage had become sealed
with a thin layer of connective tissue and had been filled
with clear, yellowish tissue-cage fluid. Above 1010 CFU of
exponentially growing E. coli ATCC 25922 culture was
concentrated in 1 mL of saline and injected into each
tissue-cage. Two days after infection, 0.5 mL of tissue-
cage fluid was withdrawn from each cage for a viable-
bacteria count. Piglets having above 108 CFU/mL viable
bacterial cells in tissue-cage fluid were treated with various
doses and intervals of cefquinome.
Pharmacokinetic measurements
Eighteen piglets were randomly allocated to 7 administra-
tion groups and treated at 0.1, 0.2, 0.4, 0.8, or 1.0 mg/kg of
body weight once a day (24 h interval) or 0.2 and 0.4
mg/kg of body weight twice a day (12 h interval). 0.1, 0.8,
1.0 mg/kg groups had 2 piglets and 4 tissue cages of each
group. 0.2, 0.4 mg/kg (12 h and 24 h interval) groups had
3 piglets and 6 tissue cages of each group, which had one
more piglet compared to 0.1, 0.8, 1.0 mg/kg groups
respectively because these two dosages easily induced
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mined by recommended dose which was 2 mg cefqui-
nome/kg body weight in intramuscularly once daily for
3-5 days [13] and pre-experiments data (not provided).
Cefquinome were administrated intramuscularly (intraglu-
teal muscles) for consecutive 5 times beginning on the 3rd
day after infection with E. coli ATCC 25922 for every piglet
in administration groups. The control group, three piglets,
received sterile physiological saline (1 mL) simultaneously
in the same way. Tissue-cage fluid (0.5 mL) was collected
from the cage at 1, 3, 6, 9, 12, and 24 h after each adminis-
tration in group with 24 h interval. For groups with 12 h
interval, samples were collected at 1, 3, 6, 9, 12 h after each
administration. Fluid samples were clarified by centrifuga-
tion at 3 000 ? g for 10 min and stored at -20?C.
The concentrations of cefquinome was determined using
an Agilent 1200 series high performance liquid chromatog-
raphy and an Agilent 6400 triple quadrupole mass spec-
trometer equipped with an electrospray ionization source
(HPLC-MS/MS, Agilent Technologies, USA). The chroma-
tographic separation was achieved on a Phenonenex BDS
C18 column (150 mm ? 2 mm; internal diameter, 5 μm,
Phenomenex Technologies) at 40?C with a thermostat
column oven (Agilent 1200 series, Agilent Technologies).
The mobile phase consisted of solution A (water with
0.1% formic acid, V/V) and solution B (acetonitrile) at
0.25 mL/min flow rate. The gradient elution was: 0-1 min,
5% B; 1-5.5 min, 60% B; 5.5-10 min, 5% B. The injection
volume was 5 μL.
A calibrated curve was constructed by adding a known
amount of cefquinome to blank tissue-cage fluid over con-
centrations ranged from 0.001 μg/mL to 1 μg/mL. The
lower limit of quantification (LLOQ) of cefquinome was
5 ng/mL. The recoveries of cefquinome in tissue-cage
fluid were 94.2 ? 7.34% (mean ? standard deviation, SD,
n = 5). The coefficients of variability (CV%) were all < 10%
for both intra-assay and inter-assay variation.
Pharmacokinetic/pharmacodynamic (PK/PD) indices
such as T>MIC99, T>MPC, AUC/MIC99, AUC/MPC,
Cmax/MIC99, Cmax/MPC were calculated according to a
noncompartmental analysis using WinNonlin programme
(version 6.1, Pharsight Corporation, Mountain View, CA,
USA). The liner trapezoidal rule was used to calculate the
area under the concentration-time curve (AUC). All
PK/PD indices calculations referred to the 12 h and 24 h
dosing interval immediately following the fifth injection
after finishing administration using the cefquinome
concentrations in tissue cage fluid.
Loss of susceptibility to cefquinome
Potential loss of susceptibility was monitored in tissue-
cage fluid (0.5 mL/cage) obtained daily before and dur-
ing the cefquinome treatment (after every administra-
tion) and 24 and 48 h after the termination of treatment.To amplify cultures, half of each sample was incubated
overnight in drug-free Mueller-Hinton broth, and then
the MIC was determined with the CLSI [17] agar dilu-
tion method. The other half of each sample was serially
diluted with sterile physiological saline and applied to
agar either lacking drug or containing cefquinome at
1 ? MIC of the starting culture. After incubation at 37?C
for 24-48 h, colonies were calculated, and the fraction of
mutants in the population was calculated.
Resistant mutants (growing on 1 ? the MIC of cefquinome-
containing agar) were also chosen randomly from sam-
ples that had cefquinome concentrations predominantly in
the lower, middle, or upper part of the selection window
with 12 h or 24 h interval administration. Single colonies
of these mutants were passaged 5 times on drug-free agar,
and the MIC to cefquinome was then determined.
Statistical analysis
Fisher ? s exact test was used for statistical analysis of the
PK/PD data, with an infected but untreated set of piglets
(3 piglets, 6 tissue-cages) as a control. P < 0.05 was consid-
ered to be statistically significant.
Results
Bacteria count in tissue-cage model
Two perforated tissue-cages were implanted into each
piglet. When above 1010 CFU bacteria were injected into
an implanted cage, no severe illness or distress oc-
curred during a 10-day observation. Bacterial concen-
trations remained constant at about 108 CFU/mL when
piglets were treated intramuscularly for 5 times with
sterile physiological saline once or twice daily.
Administration of cefquinome at 0.1 mg/kg at 24 h
interval slightly reduced bacterial numbers compared to
the control during the trial. Administration of cefqui-
nome at 0.2 and 0.4 mg/kg at 24 h interval observably
reduced bacterial numbers for the first 4 administra-
tions, but bacterial growth was observed later during
treatment and during post-treatment. Administration of
cefquinome at 0.8 and 1.0 mg/kg at 24 h interval caused
bacterial numbers to decrease throughout treatment and
remain low during the growth recovery phase (Figure 1).
Cefquinome concentrations
The values of MIC, MIC99, and MPC were 0.064 μg/mL,
0.06 μg/mL, and 0.16 μg/mL in present study, respectively.
Cefquinome concentrations, determined in samples of
tissue-cage fluid collected at various time points over
several days, are shown in Figure 2 (panels A1-A8). There
were totally 34 tissue cages analyzed and another 2 tissue
cages were excluded because of bacterial pollution. And the
cefquinome concentrations shown for each of the 8 groups
were the means of the concentrations from all animals/
tissue cage fluids selected for those groups. The boundaries
Figure 1 Effect of cefquinome dose on bacterial inhibition in the tissue-cage model. Tissue-cage implantation and Escherichia coli ATCC
25922 infection were done as described in Materials and Methods. Three days after infection, various doses (0, 0.1, 0.2, 0.4, 0.8, or 1.0 mg/kg of
body weight, each piglet has tissue-cages) of cefquinome were administered intramuscular once daily for 5 days (indicated by the arrow).
Bacterial colony-forming units in tissue-cage fluid was monitored at 24 h intervals beginning 1 day before the initiation of cefquinome in treatment
and ending 2 days after the termination of cefquinome treatment.
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0.06 μg/mL (MIC99) and 0.16 μg/mL (MPC) by agar plate
assays, which were the average values determined in the
five independent experiments. There are 8 groups (A1-A8)
to display the different classifications (lower, higher, partially
inside, totally inside) of cefquinome concentrations based
on the MSW boundary.Figure 2 Effect of actual cefquinome concentration on loss of suscep
Escherichia coli ATCC 25922 infection were done as described in Meterials a
fluid 2 days after infection were treated with various intramuscular doses o
after infection. The dosage, administration at hour or day 0 of the x-axis, pr
received 1.0 mg/kg; A3, 4 received 0.2 mg/kg and 2 received 0.4 mg/kg; A
0.4 mg/kg; A6, 2 received 0.2 mg/kg and 3 received 0.4 mg/kg; A7, 1 recei
Cefquinome concentration in tissue-cage fluid was monitored at the indica
boundaries of the mutant selection window (the MIC99 and MPC) were det
was sampled for bacteria at 24 h and 12 h intervals for 7 times starting imm
Loss of susceptibility (panels B1-B8) was monitored as an increase in MIC
(panels C1-C8) in each group of piglets was determined daily as the num
the number that grew on drug-free agar.MICs and mutant fraction
Samples of E. coli ATCC 25922 in tissue-cage fluid after
treatment with various doses were examined for sus-
ceptibility to cefquinome. Increases in MICs were read-
ily observed (Figure 2, panels B3-B8) when cefquinome
concentrations were partially or totally inside the selec-
tion window (Figure 2, panels A3-A8).tibility and mutant enrichment. Tissue-cage implantation and
nd Methods. Piglets having above 1 ? 10 8 CFU/mL E.coli in tissue-cage
f cefquinome once daily and twice daily for 5 times beginning 3 days
otocol for each panel was as follows: A1, 4 received 0.1 mg/kg; A2, 3
4, 4 received 0.8 mg/kg and 1 received 1.0 mg/kg; A5, 3 received
ved 0.2 mg/kg and 4 received 0.4 mg/kg; A8, 3 received 0.2 mg/kg.
ted times after the administration of each dose (panels A1-A8). The
ermined with the E.coli inoculum by agar plate assays. Tissue-cage fluid
ediately before the administration of the first dose of cefquinome.
averaged for all piglets in the group. The fraction of resistant mutants
ber of colonies grown on cefquinome-containing agar (MIC) relative to
Zhang et al. BMC Veterinary Research 2014, 10:297 Page 5 of 8
http://www.biomedcentral.com/1746-6148/10/297When cefquinome concentrations maintained either
below the MIC99 (Figure 2, panel A1) or above the MPC
(Figure 2, panel A2), no MIC increase, either during (days
0-5) or after therapy (days 6-7), was observed (Figure 2,
panels B1 and B2). When cefquinome concentrations over-
lapped the lower window boundary (MIC99) and the Cmax
was lower than the middle concentration (0.11 μg/mL) of
the MSW during treatment (Figure 2, panel A3), decreased
susceptibility (MIC increase) was detected in 1 of 6 cages
and the MIC increased to 0.512 μg/mL at day 7 (Figure 2,
panel B3). When cefquinome concentrations crossed the
upper boundary of the window (MPC) and the Cmin was
higher than the middle concentration of the MSW during
treatment (Figure 2, panel A4), loss of susceptibility was de-
tected in 1 of 5 cages and the MIC also increased to
0.512 μg/mL at day 7 (Figure 2, panel B4). As drug concen-
trations were over the MIC99 and T>MPC did not exceed
25% of interval, susceptibility decreased in 8 of 8 cages and
the MIC increased to 2.048 μg/mL at day 7 (Figure 2,
panels B5 and B6), regardless of the mean concentration lo-
cated into the lower (Figure 2, panel A6) or upper (Figure 2,
panel A5) part of the selection window. In addition, cefqui-
nome susceptibility decreased in all 8 cages and the MIC
increased to 0.512 μg/mL at day 5 (Figure 2, panels B7 and
B8) in the condition of 12 h interval with drug concentra-
tions approximately the same with the condition of 24 h
interval (Figure 2, panels A5 and A6). The detailed infor-
mation is shown in Table 1.Table 1 Values of PK/PD parameters and change of MIC
in different cefquinome concentrations (18 piglets, 7
groups, treated at 0.1, 0.2, 0.4, 0.8, or 1.0 mg/kg of body
weight once a day or 0.2 and 0.4 mg/kg of body weight
twice a day)
Groups PK/PD parameters Interval (h) MIC (μg/mL)
A1 (N = 2) T > MIC99% = 0 24 Total 4 cages,
no increase
A2 (N = 2) T > MPC% = 100% 24 Total 3 cages,
no increase
A3 (N = 3) T > MIC99% = 25% 24 1/total 6 cages,
increased to 0.512
T >MPC% = 0
TMSW% = 25%
A4 (N = 3) T > MIC99% = 100% 24 1/total 5 cages,
increased to 0.512
T > MPC% = 50%
TMSW% = 50%
A5 (N = 2)
& A6 (N = 3)
T > MIC99% = 100% 24 8/total 8 cages,
increased to 2.048
T >MPC% ≤ 25%
75% ≤ TMSW% ≤ 100%
A7 (N = 3)
& A8 (N = 2)
T > MIC99% = 100% 12 8/total 8cages,
increased to 0.512
T >MPC% = 0
TMSW% = 100%
Cefquinome PK/PD values were determined from tissue cage fluids using total
drug concentrations. N is the animal number per group.The fraction of mutants dramatically increased (>104
fold) when drug concentrations fell inside the selection
window. And there was no difference no matter whether
the concentration partly or wholly dropped into the
MSW (Figure 2, panels C3-C8). Overall, these data have
shown that the selection window boundaries determined
by agar plate assays fit well with results obtained in vivo
in piglets for cefquinome.
Correlation of PK/PD indices with mutant enrichment and
amplification
PK/PD indices, such as AUC24 h/MIC99 (where AUC24 h
is the area under the drug concentration time curve in a
24 h interval) and time above the MIC99, provide an
empirical way to relate antimicrobial dose to favorable
treatment effect for bactericidal agents. Relationships be-
tween PK/PD indices, determined as steady-state values
after the fifth dose, and lost of susceptibility are shown
in Table 2. For cephalosporin, T>MIC99 is the index
most commonly associated with restricting susceptible
cell growth. Only 1 of 10 tissue-cages lost susceptibility
when T>MIC99≤6 h or T>MIC99%≤25% (Table 2 and
Figure 2, panels A1 and A3). T>MPC is probably the
appropriate parameter for the upper boundary of the
selection window. Only 1 of 8 tissue-cages was lost sus-
ceptibility when T>MPC≥12 h or T>MPC%≥50%
(Table 2 and Figure 2, panels A2 and A4). Loss of bac-
terial susceptibility occurred in 16 of 16 tissue-cages (8
for 24 h interval and 8 for 12 h interval) when TMSW%
was between 25% and 100%, with T>MPC%≤25% simul-
taneously (Table 2 and Figure 2, panels A5-A8).
Other PK/PD indices also showed statistically significant
(P < 0.05) correlations with the selection of resistance
(Table 2). When AUC24 h/MIC99 and AUC24 h/MPC were
considered, the mutant selection window extended from
32.84 h to 125.64 h and from 12.83 h to 49.09 h, respect-
ively. In another example, the selection window extended
from 1.32 to 4.26 and from 0.52 to 1.66, respectively, when
maximum concentration Cmax/MIC99 and Cmax/MPC were
considered.
Discussion
Antimicrobial resistance becomes an increasingly serious
problem that is likely to require attention at many levels
[2]. Issues concerning dosing are addressed by the mu-
tant selection window hypothesis [18]. The fundamental
difference between the traditional MIC-based strategies
and the MPC-based approach is that the former requires
bacteria to acquire only 1 mutation for growth in the pre-
sence of drug, whereas the latter requires 2 or more [19].
Considering the boundaries of the selection window, it
need to be predictable on the basis of data obtained by
clinical microbiological laboratories. Previous work has
shown that static agar plate values of MIC99 and MPC
Table 2 Correlation of pharmacokinetic/





























All PK/PD parameters were determined using total drug concentrations in
tissue cage fluid. Total 34 tissue cages were analyzed and 2 tissue cages
excluded because of bacterial pollution.
aTine in the window (Tmsw) is not presented in the table because it fell into
2 categories.
bP values were calculated by Fisher ?s exact test, with a set of 3 infected but
untreated piglets (6 tissue-cages) used as a control. High values indicate no
difference with the control.
Figure 3 Effect of cefquinome exposure on recovery of total
and resistant bacteria. Concentrations of total bacteria and
resistant mutants were determined in aliquots of tissue-cage fluid
obtained at the indicated time points after the initiation of treatment.
Representative two examples (one piglet each dose regimen) are
shown for piglets in which the cefquinome concentration was inside
the mutant selection window, as determined in Figure 2.
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boundaries obtained in in vitro models [4,6,8,20]. The data
in Figure 2 demonstrate that agar plate determinations of
MIC99 and MPC fit well with the boundaries of the selec-
tion window seen in vivo at the site of infection for
cefquinome.
In PK/PD model, the T>MIC (for time-dependent
drugs) and AUC24 h/MIC (for concentration-dependent
drugs) can be used empirically to predict favorable effect
when susceptible populations are considered [21]. Herein,
the T>MIC99 (for time-dependent drugs) or AUC24 h/
MIC99 (for concentration-dependent drugs) can be used
to define the lower boundary of the selection window in
PK/PD combined with MSW model. For the upper
boundary of the window, as the MPC is the MIC of the
least-susceptible single-step mutant, T>MPC or AUC24 h/
MPC probably is the appropriate parameter [22]. Anin vitro study of E. coli treated with ciprofloxacin also
argued for the use of AUC24 h/MPC. Other PK/PD indi-
ces? such as Cmax/MIC99, Cmax/MPC, and time in the
window (TMSW %)? also showed a statistically significant
(P < 0.05) correlation with the selection of resistance.
In present study, a correction is required when concentra-
tions are high enough to kill the resistant (the cefquinome
concentration needed to exceed the MPC for over half the
dosing period to restrict the recovery of mutants). Keeping
antimicrobial concentrations above the MPC >12 h
(T>MPC% >50%) or AUC24 h/MPC >49.09 h is a straight-
forward way to restrict the acquisition of resistance in this
study. However, it is still complicated that what concentra-
tions made the susceptible strains acquired resistance inside
the window. In previous investigation, concentrations at the
center of the window were suitable for selecting a double
mutant in an in vitro model [23]. In present piglet/perfo-
rated-tissue-cage system, the drug concentration needed to
be inside the window for ≥75% of the interval for enrich-
ment mutants when those concentrations fluctuated above
and below the MPC. When the concentrations fluctuated
above and below the MIC99, they needed to be inside the
window for only 25% of the interval. This difference prob-
ably results from: (1) more abundant preexisting resist-
ant mutant subpopulations being able to survive and
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ing of some mutants when drug concentrations are close
to the top of the window; (3) the organism have a better
growth fitness at a low concentration than a high condi-
tion [22].
The fraction of mutants can increase either by mutant
amplification (outgrowth of mutant cells) or by mutant en-
richment (killing of susceptible cells). To distinguish these
situation, we determined the absolute number both of total
and resistant bacteria. When drug concentrations were in-
side the selection window, the total population size de-
creased and then gradually increased. However, the mutant
numbers were initially constant, indicating that a fractional
increase may result from preferential killing of susceptible
cells. After several times of administration, amplification of
mutants was observed at last (Figure 3). Thus, the selection
of cefquinome-resistant mutants in vivo probably arose
from both mutant amplification (outgrowth of mutant
cells) and mutant enrichment (killing of susceptible cells).
Beta-lactam antibiotics, including penicillins, cephalospo-
rins and carbapenems, are widely used not only in human
but also in vet clinic. Production of beta-lactamase is one of
major resistance mechanisms in gram-negative bacteria,
which mostly refers to extended-spectrum beta-lactamases
(ESBLs) existing largely in microorganisms of the family
Enterobacteriaceae [24]. It was complicated to confirm the
mechanism of acquisition resistant genes for sensitive
strains exposure of antimicrobial agents, such as chromo-
some gene mutant and plasmid acquisition. The present
data could not display how the resistant property was pro-
duced by E. coli ATCC 25922. More molecular technique,
the PCR of target gene, the PFGE of original strain and mu-
tants, and plasmid profiles analysis at least, should be ap-
plied to determine the mutant gene which caused bacterial
resistance. Those are the mainly study purposes of the next
task in laboratory animals.
Conclusions
In conclusion, the data in Figure 2 demonstrate that the
mutant selection window agar plate determinations fit
well with the piglets infected with E. coli ATCC 25922 of
cefquinome treatment in vivo. Because agar plate assays
are routine in clinical laboratories, implementation of
selection window dosing strategy is feasible. The next
steps for the tissue-cage model are to obtain more data
to confirm the boundary of MSW. For example, more
virulent strains should be used to allow bacterial popula-
tions to reach 1010 cells by in vivo growth from a smaller
inoculum in further study.
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